Dipesh Uprety, Assistant Professor of Thoracic Oncology at the Barbara Ann Karmanos Cancer Institute, shared an article by Mark M. Awad on X:
“Phase III CheckMate-816 Journal of Clinical Oncology Neoadjuvant Nivo + Ipi vs Chemo:-
- Md EFS 54.8 mo vs 20.4 mo.
- pCR 20.4 vs 4.6 MPR 28.3 vs 14.8%.
- pCR or MPR had higher baseline 4-gene inflammatory scores than those without in IO arm.”
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.
Authors: Mark M. Awad, et al.
Dipesh Uprety, Assistant Professor of Thoracic Oncology at the Barbara Ann Karmanos Cancer Institute, specializes in treating lung cancer, mesothelioma, thymoma, and thymic carcinoma. He also serves as the Editor-in-Chief of The Cancer News, an authoritative resource on cancer-related topics.